Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorIranzo Gómez, Patricia
dc.contributor.authorCallejo Perez, Ana
dc.contributor.authorAssaf Pastrana, Juan David
dc.contributor.authorMolina, Gaspar
dc.contributor.authorLopez, Daniel Esteban
dc.contributor.authorGarcía Illescas, David
dc.contributor.authorPardo Aranda, Nuria
dc.contributor.authorNavarro Mendivil, Alejandro
dc.contributor.authorMartínez Marti, Alexandre
dc.contributor.authorCedres Perez, Susana
dc.contributor.authorCarbonell, Caterina
dc.contributor.authorFrigola Rissech, Joan
dc.contributor.authorAmat, Ramon
dc.contributor.authorFelip Font, Enriqueta
dc.date.accessioned2022-09-12T09:14:36Z
dc.date.available2022-09-12T09:14:36Z
dc.date.issued2022-05-30
dc.identifier.citationIranzo P, Callejo A, Assaf JD, Molina G, Lopez DE, Garcia-Illescas D, et al. Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer. Front Med. 2022 May 30;9:875974.
dc.identifier.issn2296-858X
dc.identifier.urihttp://hdl.handle.net/11351/8145
dc.descriptionCorticosteroids; Efficacy; Immune checkpoint inhibitors
dc.description.abstractIn recent years, immunotherapy-based regimens have been included into the treatment's algorithm of several cancer types. Programmed death-1 (PD-1) and cytotoxic T lymphocyte antigen-4 (CTLA-4) interact with their ligands found on the surface of antigen presenting cells (APC) or tumor cells (PD-L1/2 and CD80/86). Through these interactions, stimulatory or inhibitory signals are established. Immune checkpoint inhibitors (ICIs), block these interactions, and when administered not only as monotherapy but also as part of combination regimens, have shown to improve survival results in multiple advanced cancers leading to an increasing number of patients treated with ICI and, as a consequence, a rise in the number of patients developing immune-related adverse events (irAEs). Presence of irAEs has been associated with greater benefit from treatment, especially when blocking PD-L1. Recent data suggests that treatment benefit persists after discontinuation of ICIs due to a treatment related adverse event, regardless of the grade. Patients experiencing grade 3-4 irAEs are at risk of toxicity recurrence after reintroducing immunotherapy and therefore, the decision to resume the treatment is challenging. In these cases, a multidisciplinary approach is always needed and several factors should be considered. Management of severe toxicities may require systemic corticosteroids which can impact on T-cell function. Due to their immunosuppressive properties, it is necessary to deeper determine how corticosteroids influence responses. In terms of overall survival (OS), the use of steroids as therapy for irAEs seems not to reduce OS and several studies have reported durable responses in patients experiencing autoimmune toxicities treated with corticosteroids.
dc.language.isoeng
dc.publisherFrontiers Media
dc.relation.ispartofseriesFrontiers in Medicine;9
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectCàncer - Immunoteràpia
dc.subjectMedicaments - Efectes secundaris
dc.subjectCàncer - Complicacions
dc.subject.meshAntineoplastic Agents, Immunological
dc.subject.mesh/adverse effects
dc.subject.meshNeoplasms
dc.subject.mesh/therapy
dc.titleOverview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3389/fmed.2022.875974
dc.subject.decsinmunoterapia antineoplásica
dc.subject.decs/efectos adversos
dc.subject.decsneoplasias
dc.subject.decs/terapia
dc.relation.publishversionhttps://doi.org/10.3389/fmed.2022.875974
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Iranzo P, Callejo A, Assaf JD, Molina G, Lopez DE, Garcia-Illescas D, Pardo N, Navarro A, Martinez-Marti A, Cedres S, Felip E] Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Carbonell C, Frigola J, Amat R] Thoracic Cancers Translational Genomics Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid35707528
dc.identifier.wos000811872600001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record